INDUSTRY × Thyroid Neoplasms × 1 year × Clear all
NCT07124000 2026-02-24

DP-04

AstraZeneca

Recruiting
100 enrolled
NCT05366881 2026-01-20

CAMPERR

Adela, Inc

Recruiting
7,000 enrolled
NCT03899792 2026-01-06

LIBRETTO-121

Eli Lilly and Company

Phase 1/2 Active not recruiting
36 enrolled 13 charts 2 FDA
NCT03157128 2025-10-20

LIBRETTO-001

Eli Lilly and Company

Phase 1/2 Active not recruiting
857 enrolled 3 FDA
NCT06336148 2025-10-15

A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors

Actym Therapeutics, Inc.

Phase 1 Terminated
10 enrolled
NCT02628067 2025-09-22

KEYNOTE 158

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting
1,609 enrolled 5 FDA
NCT03093116 2025-07-10

TRIDENT-1

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
500 enrolled 2 FDA
NCT06239194 2025-06-22

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

ModeX Therapeutics, An OPKO Health Company

Phase 1/2 Recruiting
115 enrolled
NCT03037385 2025-05-31

ARROW

Hoffmann-La Roche

Phase 1/2 Completed
590 enrolled 58 charts 5 FDA